Literature DB >> 25880962

Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer.

Pebbles Fagan1, Eric T Moolchan, Pallav Pokhrel, Thaddeus Herzog, Kevin D Cassel, Ian Pagano, Adrian A Franke, Joseph Keawe'aimoku Kaholokula, Angela Sy, Linda A Alexander, Dennis R Trinidad, Kari-Lyn Sakuma, C Anderson Johnson, Alyssa Antonio, Dorothy Jorgensen, Tania Lynch, Crissy Kawamoto, Mark S Clanton.   

Abstract

OBJECTIVES: We examined biomarkers of tobacco smoke exposure among Native Hawaiians, Filipinos, and Whites, groups that have different lung cancer risk.
METHODS: We collected survey data and height, weight, saliva, and carbon monoxide (CO) levels from a sample of daily smokers aged 18-35 (n = 179). Mean measures of nicotine, cotinine, cotinine/cigarettes per day ratio, trans 3' hydroxycotinine, the nicotine metabolite ratio (NMR), and expired CO were compared among racial/ethnic groups.
RESULTS: The geometric means for cotinine, the cotinine/cigarettes per day ratio, and CO did not significantly differ among racial/ethnic groups in the adjusted models. After adjusting for gender, body mass index, menthol smoking, Hispanic ethnicity, and number of cigarettes smoked per day, the NMR was significantly higher among Whites than among Native Hawaiians and Filipinos (NMR = 0.33, 0.20, 0.19, P ≤ .001). The NMR increased with increasing White parental ancestry. The NMR was not significantly correlated with social-environmental stressors.
CONCLUSIONS: Racial/ethnic groups with higher rates of lung cancer had slower nicotine metabolism than Whites. The complex relationship between lung cancer risk and nicotine metabolism among racial/ethnic groups needs further clarification.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25880962      PMCID: PMC4431074          DOI: 10.2105/AJPH.2014.302492

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  61 in total

1.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

2.  Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

3.  Race, gender, and nicotine metabolism in adolescent smokers.

Authors:  Mark L Rubinstein; Saul Shiffman; Michelle A Rait; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2012-12-13       Impact factor: 4.244

Review 4.  Nicotine: specific role in angiogenesis, proliferation and apoptosis.

Authors:  Alessio Cardinale; Candida Nastrucci; Alfredo Cesario; Patrizia Russo
Journal:  Crit Rev Toxicol       Date:  2011-11-04       Impact factor: 5.635

5.  A global measure of perceived stress.

Authors:  S Cohen; T Kamarck; R Mermelstein
Journal:  J Health Soc Behav       Date:  1983-12

6.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Authors:  Noritaka Ariyoshi; Masami Miyamoto; Yuri Umetsu; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yu-Ichi Sawamura; Jun Yokota; Nobuo Nemoto; Kunio Sato; Tetsuya Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

7.  Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

8.  Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes.

Authors:  H Yamazaki; Y Inui; C H Yun; F P Guengerich; T Shimada
Journal:  Carcinogenesis       Date:  1992-10       Impact factor: 4.944

9.  Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure.

Authors:  Neal L Benowitz; Katherine M Dains; Delia Dempsey; Brenda Herrera; Lisa Yu; Peyton Jacob
Journal:  Nicotine Tob Res       Date:  2009-06-12       Impact factor: 4.244

10.  Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.

Authors:  Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more
  3 in total

Review 1.  Biomarker development in the precision medicine era: lung cancer as a case study.

Authors:  Ashley J Vargas; Curtis C Harris
Journal:  Nat Rev Cancer       Date:  2016-07-08       Impact factor: 60.716

Review 2.  Biosignature Discovery for Substance Use Disorders Using Statistical Learning.

Authors:  James W Baurley; Christopher S McMahan; Carolyn M Ervin; Bens Pardamean; Andrew W Bergen
Journal:  Trends Mol Med       Date:  2018-02-04       Impact factor: 11.951

3.  Increased Surgical Complications in Smokers Undergoing Radical Cystectomy.

Authors:  Niranjan J Sathianathen; Christopher J Weight; Stephanie L Jarosek; Badrinath R Konety
Journal:  Bladder Cancer       Date:  2018-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.